Gate Bio

While most small molecule drugs bind and inhibit the disease-causing activity of their (typically intracellular) protein...

a16zActive

What they do

Problem

Current small-molecule drugs struggle to effectively address disease-causing extracellular proteins that drive pathology.

Solution

Gate Bio develops therapeutics that eliminate harmful extracellular proteins at the source by targeting their production and secretion pathways.

Who it's for

Pharmaceutical and biotechnology companies developing drugs for diseases driven by extracellular proteins.